5 years after launching, a singular nonprofit drug firm has printed information exhibiting that customers and well being plans saved appreciable cash on a generic most cancers drugs due to its “clear” pricing mannequin. And it maintains that the findings validate plans to distribute and — ultimately — manufacture nonetheless extra copycat medicines for the U.S. market.
The corporate — CivicaScript — was created as a automobile to fight stubbornly excessive drug costs even after dominant brand-name medicines misplaced patent safety and generic rivals entered the market. Backed principally by 18 Blue Cross Blue Protect plans, the nonprofit made its first drug accessible — a generic model of the Zytiga prostate most cancers remedy — in August 2022.
The preliminary wholesale value was $160, plus an $11 meting out price paid to pharmacies, however uptake was sluggish till it was accepted by pharmacy profit managers and different well being plans. However ultimately, the gambit labored: Between September 2023 and December 2023, sufferers saved 64% and payers saved 92% by buying the generic distributed by CivicaScript, in keeping with a brand new evaluation.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
